AIxCrypto Holdings: A New Chapter in Innovation
In a significant development for stakeholders, Qualigen Therapeutics, Inc. (NASDAQ: QLGN) has successfully held a Special Meeting of Stockholders, where all proposals received overwhelming majority approval. This milestone marks a pivotal moment as Qualigen prepares for its transformation into AIxCrypto Holdings, Inc. (NASDAQ: AIXC). This change will be officially celebrated at a Nasdaq event.
Strategic Transformation and New Leadership
The approval by shareholders confirms that Faraday Future, renowned for its innovative vision, will take the helm as the majority and controlling shareholder of the company. With an impressive shareholding estimate of around 63%, including key figures like YT Jia and Jerry Wang, Faraday Future is poised to instigate strategic enhancements.
As part of this transition, Faraday Future will assume the role of director in the reconfigured board, facilitating governance adjustments ahead of the exciting renaming event. This shift is not merely procedural but signifies a broader strategic pivot designed to align the company’s identity and operational focus with leading-edge markets, blending AI and Web3 technologies.
Unveiling the New Name and Vision
The highly anticipated renaming ceremony, set for late November, will unveil additional details regarding AIxCrypto Holdings’ new business strategy. This includes unveiling a business model that promises to position the company as a competitive force within the AI × Web3 landscape. The event will delineate a cohesive plan that spans three years, setting a developmental roadmap that reflects the latest advancements in decentralized technology.
During this ceremony, AIxCrypto will also announce the newly structured board of directors and present its strategic transformation plan. This comprehensive upgrade reflects the company's transition to a cross-disciplinary technology enterprise focusing on decentralized AI (DeAI) and intelligent trading systems.
New Ecosystem and Business Framework
The innovative change in identity signifies a crucial leap from traditional biotechnology to a focused emphasis on decentralized AI technology platforms. The dynamic relationship between AIxCrypto and Faraday Future is expected to foster cross-ecosystem collaboration, driving innovation and integration that leads to long-term growth.
This transformation encapsulates not just a rebranding but a holistic upgrade to the company’s identity, business model, and technology strategy. It fundamentally illustrates AIxCrypto’s commitment to becoming a beacon in the evolving AI and Web3 space.
Key Approvals and Future Directions
AIxCrypto has also secured essential proposal approvals during this transition, including a Subscription Agreement that allows the issuance of new shares to meet Nasdaq listing requirements. The company's plans include a 2025 Equity Incentive Plan designed to aid long-term retention of talent while aligning with shareholder interests.
As the company is now entering an execution phase aligned with its growth strategy as AIxCrypto, the leadership remains committed to communicating updates that will keep investors and stakeholders informed of progress and strategic alignment.
About Qualigen Therapeutics, Inc.
Qualigen Therapeutics (NASDAQ: QLGN) specializes in developing and commercializing innovative therapies, particularly in the oncology and immunology sectors. With growth ambitions extending to crypto asset and Web3 strategies, Qualigen is poised to blend innovative technology with market evolution to enhance global expansion.
Frequently Asked Questions
What was the nature of the proposals approved by stockholders?
The stockholders approved all proposals, including the transition of control to Faraday Future and the renaming of the company to AIxCrypto Holdings, Inc.
What significance does the renaming hold for the company?
The renaming represents a strategic shift towards integrating AI and Web3 technologies, signaling a new identity and operational focus.
How will the new business model position AIxCrypto in the market?
AIxCrypto aims to become a leading gateway to the AI × Web3 era, leveraging innovative technologies and frameworks designed for growth and collaboration.
What is the expected ownership structure after the transition?
Faraday Future is expected to have approximately 63% of ownership, with the majority of the board seats being filled by its nominees.
Who can investors contact for more information?
Investors can reach out to the Investor Relations Department of Qualigen Therapeutics for inquiries and details regarding the transition and upcoming plans.
